Search

Displaying results 6881 - 6890 of 7687 in total
  1. Drug

    Puromycin

    go.drugbank.com/drugs/DB08437
    Experimental

    Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures.

  2. Drug

    Palucorcel

    go.drugbank.com/drugs/DB17955
    Investigational

    Palucorcel is an investigational stem cell therapy consisting of human umbilical tissue-derived cells.

  3. Drug

    Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase

    go.drugbank.com/drugs/DB18681
    Experimental

    Autologous CD34+ hematopoietic stem and progenitor cells expressing adenosine deaminase is an investigational lentiviral gene therapy.

  4. Drug

    Propidium

    go.drugbank.com/drugs/DB02166
    Experimental

    Quaternary ammonium analog of ethidium; an intercalating dye with a specific affinity to certain forms of DNA and, used as diiodide, to separate them in density gradients; also forms fluorescent complexes

  5. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acut...

  6. Drug

    ISIS 325568

    go.drugbank.com/drugs/DB06099
    Investigational

    ISIS 325568 is a generation 2.2 antisense drug that targets the glucagon receptor (GCGR). It was under investigation in clinical trial NCT00519727 (Safety Study of ISIS 325568 in Healthy Volunteers) for lowering blood glucose and helping...

  7. Drug

    VLTS-589

    go.drugbank.com/drugs/DB05430
    Investigational

    VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.

  8. Drug

    MLN2222

    go.drugbank.com/drugs/DB06503
    Experimental

    MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.

  9. Drug

    Nedaplatin

    go.drugbank.com/drugs/DB13145
    ApprovedInvestigational

    Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.

  10. Drug

    Oditrasertib

    go.drugbank.com/drugs/DB21526
    Investigational

    Oditrasertib has a monoisotopic molecular weight of 295.11 Da.